The cost of dabigatran, sold under the brand name Pradaxa, varies depending on factors such as dosage, quantity, and insurance coverage. Without insurance, a 30-day supply of 150 mg capsules can range from approximately $300 to over $400 [1]. The price may differ based on the pharmacy and the specific strength of the medication.
How much does a Pradaxa prescription cost with insurance?
Insurance plans can significantly reduce the out-of-pocket cost for dabigatran. Co-pays for Pradaxa with insurance typically range from $10 to $50 for a 30-day supply, though this can depend on the specific formulary and deductible requirements of the plan [1]. Some plans may also offer co-pay assistance programs.
Are there ways to save money on dabigatran?
Patients may find cost savings through several avenues. Prescription discount cards and online pharmacies can offer lower prices than traditional brick-and-mortar stores [1]. Additionally, patient assistance programs offered by the manufacturer or independent organizations can help eligible individuals afford their medication [1]. Comparing prices across different pharmacies is also a common strategy for reducing costs.
When does the Pradaxa patent expire?
The original patent for dabigatran etexilate, the active ingredient in Pradaxa, has largely expired, opening the door for generic versions. For instance, the primary U.S. compound patent expired in 2022 [2]. However, other patents related to formulations or methods of use might still be in effect, potentially influencing the market landscape.
Are generic versions of dabigatran available?
Following patent expirations, generic versions of dabigatran have begun to enter the market in various regions. These generic alternatives offer a lower-cost option for patients and healthcare systems. The availability of generics can lead to a significant decrease in the overall cost of dabigatran treatment.
What is dabigatran used for?
Dabigatran (Pradaxa) is an anticoagulant medication used to prevent blood clots. It is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [3]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [3].
---
Sources:
[1] https://www.drugpatentwatch.com/blog/dabigatran-cost-and-savings
[2] https://www.drugpatentwatch.com/p/dabigatran-etexilate
[3] https://www.drugpatentwatch.com/drug/dabigatran-etexilate